Furthermore, it was found that inhibiting B-cell lymphoma-extra-large (Bcl-xL), which is encoded by Bcl2L1, resulted in antitumor effects in MCC cell lines, including a synergistic effect when poly (ADP-ribose) polymerase 1 (PARP) inhibitors are added [95]. Here, PARP1 is linked to Merkel cell skin cancer.